The SS18-SSX fusion oncoprotein:Friend and foe in targeted therapy for synovial sarcoma  

作　　者：GAVIN M.ANCHONDO KYRA PARKER ALEXIS BRUCE ELIZABETH CORTEZ LE SU 

机构地区：[1]Department of Biology,Jacksonville State University,Jacksonville,AL 36265,USA

出　　处：《Oncology Research》2025年第5期1001-1005,共5页肿瘤学研究(英文)

摘　　要：Synovial sarcoma is a high-grade soft tissue malignancy characterized by a unique fusion gene known as SS18-SSX.The SS18-SSX fusion protein acts as an oncogenic driver of synovial sarcoma,and it has thus been commonly accepted that disruption of SS18-SSX function represents a therapeutic means of treating synovial sarcoma,but emerging evidence suggests that upon depletion of SS18-SSX,an anti-apoptotic signal surprisingly arises to protect synovial sarcoma cell survival.In this article,we discuss the controversial roles of SS18-SSX’s transcriptional activity in synovial sarcoma biology and outline a synergistic strategy for overcoming the resistance of synovial sarcoma cells to SS18-SSX targeted therapeutics.

关 键 词：SS18-SSX Synovial sarcoma Targeted therapy 

分 类 号：R738.1[医药卫生—肿瘤]